

LITERATURE CITED

- Anderson, A.C. 2003. The process of structure-based drug design. **Chem. Biol.** 10: 787-797.
- Artico, M., R. Silvestri, E. Pagnozzi, B. Bruno, E. Novellino, G. Greco, S. Massa, A. Ettorre, A.G. Loi, F. Scintu and P. La Colla. 2000. Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. **J. Med. Chem.** 43: 1886-1891.
- Bajorath, J. 2002. Integration of virtual and high-throughput screening. **Nat. Rev. Drug Discov.** 1: 882-894.
- Balzarini, J. 1999. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. **Biochem. Pharmacol.** 58: 1-27
- Barreca, M.L., J. Balzarini, A. Chimirri, E. De Clercq, L. De Luca, H.D. Höltje, M. Höltje, A.M. Monforte, P. Monforte, C. Pannecouque, A. Rao and M. Zappala. 2002. Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. **J. Med. Chem.** 45: 5410-5413.
- _____, A. Rao, L. De Luca, M. Zappala, A. Monforte, G. Maga, C. Pannecouque, J. Balzarini, E. De Clercq, A. Chimirri and P. Monforte. 2005. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. **J. Med. Chem.** 48: 3433-3437.
- Bell, A.T. 2004. Challenges for the application of quantum chemical calculations to problems in catalysis. **Mol. Phys.** 102: 319-329.

- Benjahad, A., M. Croisy, C. Monneret, E. Bisagni, D. Mabire, S. Coupa, A. Poncelet, I. Csoka, J. Guillemont, C. Meyer, K. Andries, R. Pauwels, M. de Béthune, D.M. Himmel, K. Das, E. Arnold, C.H. Nguyen and D.S. Grierson. 2005. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1*H*)-ones: In Vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. **J. Med. Chem.** 48: 1948-1964.
- Bissantz, C., G. Folkers and D. Rognan. 2000. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. **J. Med. Chem.** 43: 4759-4767.
- Böhm, H.J. and G. Schneider, eds., 2000. **Virtual screening for bioactive molecules.** Wiley-VCH Verlag GmbH, Weinheim.
- Brooijmans, N. and I.D. Kuntz. 2003. Molecular recognition and docking algorithms. **Annu. Rev. Biophys. Biomol. Struct.** 32: 335-373.
- Carr, R. and H. Jhoti. 2002. Structure-based screening of low-affinity compounds. **DDT** 7: 522-527.
- Chan, J.H., G.A. Freeman, J.H. Tidwell, K.R. Romines, L.T. Schaller, J.R. Cowan, S.S. Gonzales, G.S. Lowell, C.W. Andrews III, D.J. Reynolds, M. St Clair, R.J. Hazen, R.G. Ferris, K.L. Creech, G.B. Roberts, S.A. Short, K. Weaver, G.W. Koszalka and L.R. Boone. 2004. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. **J. Med. Chem.** 47: 1175-1182.
- Clark, M., R.D. Cramer III and N. Van Opdenbosch. 1989. Validation of the general purpose Tripos 5.2 force field. **J. Comp. Chem.** 10: 982-1012.

Cramer, C.J. 2002. **Essentials of computational chemistry: Theories and models.** John Wiley and Sons, Ltd., England.

Cywin, C.L., J.M. Klunder, M. Hoermann, J.R. Brickwood, E. David, P.M. Grob, R. Schwartz, D. Pauletti, K.J. Barringer, C. Shih, C.L. Sorge, D.A. Erickson, D.P. Joseph and S.E. Hattox. 1998. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-aryloxymethyl- and 8-arylthiomethyldipyridodiaze-pinones. **J. Med. Chem.** 41: 2972-2984.

Das, K., J. Ding, Y. Hsiuo, A.D. Clark Jr., H. Moereels, L. Koymans, K. Andries, R. Pauwels, P.A. Janssen, P.L. Boyer, P. Clark, R.H. Smith Jr., M.B.K. Smith, C.J. Michejda, S.H. Hughes and E. Arnold. 1996. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. *J. Mol. Biol.* 264: 1085-1100.

_____, A.D. Clark Jr., P.J. Lewi, J. Heeres, M.R. de Jonge, L.M.H. Koymans, H.M. Vinkers, F. Daeyaert, D.W. Ludovici, M.J. Kukla, B. De Corte, R.W. Kavash, C.Y. Ho, H. Ye, M.A. Lichtenstein, K. Andries, R. Pauwels, M. de Be'thune, P.L. Boyer, P. Clark, S.H. Hughes, P.A.J. Janssen and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. **J. Med. Chem.** 47: 2550-2560

De Clercq, E. 1995a. Antiviral therapy for human immunodeficiency virus infections. **Clin. Microbiol. Rev.** 8: 200-239.

_____. 1995b. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV-1 infections. **J. Med. Chem.** 38: 2491-2517.

- _____. 1997. Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem? **Int. J. Antimicrob. Agents** 9: 21-36.
- _____. 1998. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. **Antiviral Res.** 38: 153-179.
- _____. 2002. Strategies in the design of antiviral drugs. **Nat. Rev. Drug. Discov.** 1: 13-25.
- _____. 2004a. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future. **Chem. Biodiv.** 1: 44-64.
- _____. 2004b. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. **Int. J. Biochem. Cell Biol.** 36: 1800–1822.
- _____. 2004c. Antiviral drugs in current clinical use. **J. Clin. Virol.** 30: 115-133.
- Ding, K., Y. Lu, Z. Nikolovska-Coleska, S. Qiu, Y. Ding, W. Gao, J. Stuckey, K. Krajewski, P.P. Roller, Y. Tomita, D.A. Parrish, J.R. Deschamps and S. Wang. 2005. Structure-based design of potent non-peptide MDM2 inhibitors. **J. Am. Chem. Soc.** 127: 10130-10131.
- Dyatkin, A.B., J.R. Brickwood and J.R. Proudfoot. 1998. A dipyrido[2,3-b:3',2'-f]azepine analog of the HIV-1 reversetranscriptase inhibitor nevirapine. **Bioorg. Med. Chem. Lett.** 8: 2169-2172.
- Fattorusso, C., S. Gemma, S. Butini, P. Huleatt, B. Catalanotti, M. Persico, M. De Angelis, I. Fiorini, V. Nacci, A. Ramunno, M. Rodriguez, G. Greco, E. Novellino, A. Bergamini, S. Marini, M. Coletta, G. Maga, S. Spadari and G. Campiani. 2005. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological

evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. **J. Med. Chem.** 48: 7153-7165.

Freeman, G.A., C.W. Andrews III, A.L. Hopkins, G.S. Lowell, L.T. Schaller, J.R. Cowan, S.S. Gonzales, G.W. Koszalka, R.J. Hazen, L.R. Boone, R.G. Ferris, K.L. Creech, G.B. Roberts, S.A. Short, K. Weaver, D.J. Reynolds, J. Milton, J. Ren, D.I. Stuart, D.K. Stammers and J.H. Chan. 2004. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. **J. Med. Chem.** 43: 5923-5936.

Griffith, R., T.T.T. Luu, J. Garner and P. A. Keller. 2005. Combining structure-based drug design and pharmacophores. **J. Mol. Graph. Model.** 23: 439-446.

Guillemont, J., E. Pasquier, P. Palandjian, D. Vernier, S. Gaurrand, P.J. Lewi, J. Heeres, M.R. de Jonge, L.M.H. Koymans, F.F.D. Daeyaert, M.H. Vinkers, E. Arnold, K. Das, R. Pauwels, K. Andries, M. de Béthune, E. Bettens, K. Hertogs, P. Wigerinck, P. Timmerman and P.A.J. Janssen. 2005. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. **J. Med. Chem.** 48: 2072-2079.

Gussio, R., N. Pattabiraman, D.W. Zaharevitz, G.E. Kellog, I.A. Topol, W.G. Rice, C.A. Schaeffer, J.W. Erickson and S.K. Burt. 1996. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: A 3D QSAR approach. **J. Med. Chem.** 39: 1645-1650

Halperin, I., B. Ma, H. Wolfson and R. Nussinov. 2002. Principles of docking: An overview of search algorithms and a guide to scoring functions. **PROTEINS: Structure, Function, and Genetics** 47: 409-443.

Heeres, J., M.R. de Jonge, L.M.H. Koymans, F.F.D. Daeyaert, M. Vinkers, K.J.A.V. Aken, E. Arnold, K. Das, A. Kilonda, G.J. Hoornaert, F. Compennolle, M. Cegla, R.A. Azzam, K. Andries, M. de Béthune, H. Azijn,

- R. Pauwels, P.J. Lewi and P.A.J. Janssen. 2005. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. **J. Med. Chem.** 48: 1910-1918.
- Himmel, D.M., K. Das, A.D. Clark Jr., S.H. Hughes, A. Benjahad, S. Oumouch, J. Guillemont, S. Coupa, A. Poncelet, I. Csoka, C. Meyer, K. Andries, C.H. Nguyen, D.S. Grierson and E. Arnold. 2005. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. **J. Med. Chem.** 48: 7582-7591.
- Hoffmann, D., B. Kramer, T. Washio, T. Steinmetzer, M. Rarey and T. Lengauer. 1999. Two-stage method for protein-ligand docking. **J. Med. Chem.** 42: 4422-4433.
- Högberg, M., C. Sahlberg, P. Engelhardt, R. Noréen, J. Kangasmetsä, N.G. Johansson, B. Öberg, L. Vrang, H. Zhang, B. Sahlberg, T. Unge, S. Lövgren, K. Fridborg and K. Bäckbro. 1999. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. synthesis and further structure-activity relationship studies of PETT analogues. **J. Med. Chem.** 42: 4150-4160.
- Hopkins A.L., J. Ren, H. Tanaka, M. Baba, M. Okamoto, D.I. Stuart and D.K. Stammers. 1999. Design of MKC-442 (Emivirine) analogues with improved activity against drug-resistant HIV mutants. **J. Med. Chem.** 42: 4500-4505.
- _____, J. Milton, R.J. Hazen, J.H. Chan, D.I. Stuart and D.K. Stammers. 2004. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. **J. Med. Chem.** 47: 5912-5922.

- Hsiou, Y., J. Ding, K. Das, A.D. Clark Jr, P.L. Boyer, P. Lewi, P.A. J. Janssen, J. Kleim. M. Rosner, S.H. Hughes and E. Arnold. 2001. The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. **J. Mol. Biol.** 309: 437-445.
- Hurst, T. 1994. Flexible 3D searching: The directed tweak technique. **J. Chem. Inf. Comput. Sci.** 34: 190-196.
- Jacobo-Molina, A. and E. Arnold. 1991. HIV reverse transcriptase structure function relationships. **Biochemistry** 30: 6351-6361.
- Jain, A.N. 1996. Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities. **J. Comput. Aided Mol. Design** 10: 427-440.
- _____. 2000. Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition. **J. Comput. Aided Mol. Design** 14: 199-213.
- _____. 2003. Surfex: Fully automatic flexible molecular docking using a molecular similarity-based search engine. **J. Med. Chem.** 46: 499-511.
- Janssen, P.A.J., P.J. Lewi, E. Arnold, F. Daeyaert, M. de Jonge, J. Heeres, L. Koymans, M. Vinkers, J. Guillemont, E. Pasquier, M. Kukla, D. Ludovici, K. Andries, M. de Béthune, R. Pauwels, K. Das, A.D. Clark Jr., Y.V. Frenkel, S.H. Hughes, B. Medaer, F. De Knaep, H. Bohets, F. De Clerck, A. Lampo, P. Williams and P. Stoffels. 2005. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1*E*)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzotrile (R278474, Rilpivirine). **J. Med. Chem.** 48: 1901-1909.

- Jensen, F. 1999. **Introduction to computational chemistry**. John Wiley and Sons, Ltd., England.
- Joly, V. and P. Yeni. 1999. Non nucleoside reverse transcriptase inhibitors. **AIDS Rev.** 1: 37-44.
- Jones, G., P. Willett, R.C. Glen, A.R. Leach and R. Taylor. 1997. Development and validation of a genetic algorithm for flexible docking. **J. Mol. Biol.** 267: 727-748.
- Jorgensen, W.L., J. Ruiz-Caro, J. Tirado-Rives, A. Basavapathruni, K.S. Anderson and A.D. Hamilton. 2006. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. **Bioorg. Med. Chem. Lett.** 16: 663-667.
- Kaldor, S.W., V.J. Kalish, J.F. Davies, B.V. Shetty, J.E. Fritz, K. Appelt, J.A. Burgess, K.M. Campanale, N.Y. Chirgadze, D.K. Clawson, B.A. Dressman, S.D. Hatch, D.A. Khalil, M.B. Kosa, P.P. Lubbehusen, M.A. Muesing, A.K. Patick, S.H. Reich, K.S. Su and J.H. Tatlock. 1997. Viracept (Nelfinavir Mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 Protease. **J. Med. Chem.** 40: 3979-3985.
- Kawanishi, N., T. Sugimoto, J. Shibata, K. Nakamura, K. Masutani, M. Ikuta and H. Hirai. 2006. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. **Bioorg. Med. Chem. Lett.** 16: 5122-5126.
- Klebe, G. 2000. Recent developments in structure-based drug design. **J. Mol. Med.** 78: 269-281.
- Kontoyianni, M., G.S. Sokol and L.M. McClellan. 2005. Evaluation of library ranking efficacy in virtual screening. **J. Comput. Chem.** 26: 11-22.

- Kramer, B., M. Rarey and T. Lengauer. 1999. Evaluation of the FlexX incremental construction algorithm for protein-ligand docking. **PROTEINS: Structure, Function and Genetics** 37: 228-241.
- Krier, M., J.X. Araujo-Junior, M. Schmitt, J. Duranton, H. Justiano-Barasan, C. Lugnier, J.J. Bourguignon and D. Rognan. 2005. Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: Application to the structure-based optimization of a phosphodiesterase 4 inhibitor. **J. Med. Chem.** 48: 3816-3822.
- Krovat, E. M., T. Steindl and T. Langer. 2005. Recent advances in docking and scoring. **Curr. Comput. Aided Drug Des.** 1: 93-102.
- Kuno, M., S. Hannongbua and K. Morokuma. 2003. Theoretical investigation on nevirapine and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method. **Chem. Phys. Lett.** 380: 456-463.
- _____, N. Seki, S. Tsujimoto, I. Nakanishi, T. Kinoshita, K. Nakamura, T. Terasaka, N. Nishio, A. Sato and T. Fujii. 2006. Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. **Eur. J. Pharmacol.** 534: 241-249.
- Kuntz, I.D., J.M. Blaney, S.J. Oatley, R. Langridge and T.E. Ferrin. 1982. A geometric approach to macromolecule-ligand interactions. **J. Mol. Biol.** 161: 269-288.
- Lawtrakul L., A. Beyer, S. Hannongbua and P. Wolschann. 2004. Quantitative structural rearrangement of HIV-1 reverse transcriptase on binding to non-nucleoside inhibitors. **Mh. Chem.** 135: 1033-1046.
- Leach, A.R. 1996. **Molecular modelling.** Longman Singapore Publishers (Pte), Ltd., Singapore.

- Lind, K., Z. Du, K. Fujinaga, B. Peterlin and T. James. 2002. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. **Chem. Biol.** 9: 185–193.
- Lindberg, J., S. Sigurdsson, S. Lowgren, H.O. Andersson, C. Sahlberg, R. Noreen, K. Fridborg, H. Zhang and T. Unge. 2002. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. **Eur. J. Biochem.** 269: 1670-1677.
- Lyne, P.D. 2002. Structure-based virtual screening: an overview. **DDT** 7: 1047-1055.
- Mai, A., G. Sbardella, M. Artico, R. Ragno, S. Massa, E. Novellino, G. Greco, A. Lavecchia, C. Musiu, M. La Colla, C. Murgioni, P. La Colla and R. Loddo. 2001. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. **J. Med. Chem.** 44: 2544-2554.
- Mao, C., E.A. Sudbeck, T.K. Venkatachalam and F.M. Ucken. 2000. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. **Biochem. Pharm.** 60: 1251-1265.
- Marrone, T.J., J.M. Briggs and J.A. McCammon. 1997. Structure-based drug design: Computational advances. **Annu. Rev. Pharmacol. Toxicol.** 37: 71-90.
- Martin, Y.C. 1992. 3D database searching in drug design. **J. Med. Chem.** 35: 2145-2154.
- McConkey, B.J., V. Sobolev and M. Edelman. 2002. The performance of current methods in ligand–protein docking. **Curr. Sci.** 83: 845-856.

- Mei, Y., X. He, Y. Xiang, D.W. Zhang and J.Z.H. Zhang. 2005. Quantum study of mutational effect in binding of efavirenz to HIV-1 RT. **PROTEINS: Structure, Function, and Bioinformatics** 59: 489-495.
- Menendez-Arias, L. 2002. Targeting HIV: antiretroviral therapy and development of drug resistance. **Trends Pharmacol. Sci.** 23: 381-388.
- Mestres, J. 2002. Virtual screening: a real screening complement to high-throughput screening. **Biochem. Soc. Trans.** 30: 797-799.
- Nissink, J.W.M., C. Murray, M. Hartshorn, M.L. Verdonk, J.C. Cole and R. Taylor. 2002. A new test set for validating predictions of protein-ligand interaction. **PROTEINS: Structure, Function, and Genetics** 49: 457-471.
- Nunriam, P., M. Kuno, S. Saen-oon and S. Hannongbua. 2005. Particular interaction between efavirenz and the HIV-1 reverse transcriptase binding site as explained by the ONIOM2 method. **Chem. Phys. Lett.** 405: 198-202.
- Oprea, T.I. 2002. Virtual screening in lead discovery: A viewpoint. **Molecules** 7: 51-62.
- Orry, A.J.W., R.A. Abagyan and C.N. Cavasotto. 2006. Structure-based development of target-specific compound libraries. **DDT.** 11: 261-266.
- Pauwel, R. 2004. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. **Curr. Opin. Pharmacol.** 4: 437-446.
- Pata, J.D., W.G. Stirtan, S.W. Goldstein and T.A. Steitz. 2004. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. **Proc. Natl. Acad. Sci. USA.** 101: 10548-10553.

Petersen, L., P.T. Jørgensen, C. Nielsen T.H. Hansen, J. Nielsen and E.B. Pedersen. 2005. Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, Emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach. **J. Med. Chem.** 48: 1211-1220.

Ragno, R., A. Mai, G. Sbardella, M. Artico, S. Massa, C. Musiu, M. Mura, F. Marturana, A. Cadeddu and P. La Colla. 2004. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3*H*)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. **J. Med. Chem.** 47 : 928-934.

_____, M. Artico, G. De Martino, G. La Regina, A. Coluccia, A.D. Pasquali and R. Silvestri. 2005. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active *N*-(2-hydroxyethyl)carboxamide and *N*-(2-hydroxyethyl)carbohydrazide derivatives. **J. Med. Chem.** 48: 213-223.

_____, A. Coluccia, G. La Regina, G. De Martino, F. Piscitelli, A. Lavecchia, E. Novellino, A. Bergamini, C. Ciaprini, A. Sinistro, G. Maga, E. Crespan, M. Artico and R. Silvestri. 2006. Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. **J. Med. Chem.** 49: 3172-3184.

Ranise, A., A. Spallarossa, S. Schenone, O. Bruno, F. Bondavalli, L. Vargiu, T. Marceddu, M. Mura, P. La Colla and A. Pani. 2003. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: A novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives. **J. Med. Chem.** 46: 768-781.

- _____, S. Cesarini, F. Bondavalli, S. Schenone, O. Bruno, G. Menozzi, P. Fossa, L. Mosti, M. La Colla, G. Sanna, M. Murreddu, G. Collu, B. Busonera, M.E. Marongiu, A. Pani, P. La Colla and R. Loddò. 2005. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives. **J. Med. Chem.** 48: 3858-3873.
- Rarey, M., B. Kramer, T. Lengauer and G. Klebe. 1996. A fast flexible docking method using an incremental construction algorithm. **J. Mol. Biol.** 261: 470-489.
- _____ and T. Lengauer. 1999. Docking of hydrophobic ligands with interaction-based matching algorithms. **Bioinformatics** 15: 243-250.
- Rastelli, G., Z. Tian, Z. Wang, D. Mylesa and Y. Liu. 2005. Structure-based design of 7-carbamate analogs of geldanamycin. **Bioorg. Med. Chem. Lett.** 15: 5016-5021.
- Ren, J., R. Esnouf, E. Garmen, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart and D. Stammers. 1995. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. **Nat. Struct. Biol.** 2: 293-302.
- _____, J. Milton, K.L. Weaver, S.A. Short, D.I. Stuart and D.K. Stammers. 2000. Structural basis for the resilience of efavirenz (DMP-266) to drug resistant mutations in HIV-1 reverse transcriptase. **Structure Fold. Res.** 8: 1089-1094.
- _____, C. Nichols, L. Bird, P. Chamberlain, K. Weaver, S. Short, D.I. Stuart and D.K. Stammers. 2001. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. **J. Mol. Biol.** 312: 795-805.

- _____ and D.K. Stammers. 2005. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. **Trends Pharmacol. Sci.** 26: 4-7.
- Roche, O., R. Kiyama and L. B. Charles III. 2001. Ligand-protein database: Linking protein-ligand complex structures to binding data. **J. Med. Chem.** 44: 3592-3598.
- Ruppert, J., W. Welch and A.N. Jain. 1997. Automatic identification and representation of protein binding sites for molecular docking. **Protein Science** 6: 524-533.
- Rutenber, E. and R. Stroud. 1996. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity. **Structure** 4: 1317-1324.
- Saen-oon, S., M. Kuno and S. Hannongbua. 2005. Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl *TIBO* complex structures: Quantum chemical calculations based on the ONIOM method. **PROTEINS: Structure, Function, and Bioinformatics** 61: 859-869.
- Sarafianos, S.G., K. Das, S.H. Hughes and E. Arnold. 2004. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. **Curr. Opin. Struct. Biol.** 14: 716-30.
- Schindler, T., W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson and J. Kuriyan. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. **Science** 289: 1938-1942.
- Schneider, G. and H.J. Böhm. 2002. Virtual screening and fast automated docking methods. **DDT** 7: 64-70.

- Seifert, M.H.J., K. Wolf and D. Vitt. 2003. Virtual high-throughput in silico screening. **Biosilico** 1: 143-149.
- Sheridan, R.P., R. Nilakantan, A. Rusinko III, N. Bauman, K.S. Haraki and R. Venkataraghavan. 1989. 3DSEARCH: a system for three-dimensional substructure searching. **J. Chem. Inf. Comput. Sci.** 29: 255-260.
- Shoichet, B.K. 2004. Virtual screening of chemical libraries. **Nature** 432: 862-865.
- Silvestri, R., G. De Martino, G. La Regina, M. Artico, S. Massa, L. Vargiu, M. Mura, A.G. Loi, T. Marceddu and P. La Colla. 2003. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: Synthesis and SAR studies. **J. Med. Chem.** 46: 2482-2493.
- _____, M. Artico, G. De Martino, G. La Regina, R. Loddo, M. La Colla and P. La Colla. 2004. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. **J. Med. Chem.** 47: 3892-3896.
- Smerdon, S.J., J. Jäger, J. Wang, L.A. Kohlstaedt, J.M. Chirino, J.M. Friedman, P.A. Rice and T.A. Steitz. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. **Proc. Natl. Acad. Sci. USA** 91: 3911-3915.
- Tantillo, C., J. Ding, A. Jacobo-Molina, R.G. Nanni, P.L. Boyer, S.H. Hughes, R. Pauwels, K. Andries, P.A. Janssen and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance. **J. Mol. Biol.** 243: 369-387.

- Taylor, R. 2002. Life-science applications of the cambridge structural database. **Acta. Cryst. D58**: 879-888.
- Tilley, J.W., L. Chen, D.C. Fry, S.D. Emerson, G.D. Powers, D. Biondi, T. Varnell, R. Trilles, R. Guthrie, F. Mennona, G. Kaplan, R.A. LeMahieu, M. Carson, R. Han, C.M. Liu, R. Palermo and G. Ju. 1997. Identification of a small molecule inhibitor of the IL-2/IL-2R α receptor interaction which binds to IL-2. **J. Am. Chem. Soc.** 119: 7589-7590.
- Titmuss, S.J., P.A. Keller and R. Griffith. 1999. Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase. **Bioorg. Med. Chem.** 7: 1163-1170.
- Van Drie, J.H. 1997. Strategies for the determination of pharmacophoric 3D database queries. **J. Comput. Aided Mol. Design** 11: 39-52.
- Varghese, J. 1999. Development of neuraminidase inhibitors as anti-influenza virus drugs. **Drug Dev. Res.** 46: 176-196.
- Verdonk, M.L., J.C. Cole, M.J. Hartshorn, C.W. Murray and R.D. Taylor. 2003. Improved protein-ligand docking using GOLD. **PROTEINS: Structure, Function, and Genetics** 52: 609-623.
- Wang, J., X. Kang, I.D. Kuntz and P.A. Kollman. 2005. Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA. **J. Med. Chem.** 48: 2432-2444.
- Wiesmann, C., H. Christinger, A. Cochran, B. Cunningham, W. Fairbrother, C. Keenan, G. Meng and A. DeVos. 1998. Crystal structure of the complex between VEGF and a receptor-blocking peptide. **Biochemistry** 37: 17765-17772.

- Welch, W., J. Ruppert and A.N. Jain. 1996. Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. **Chem. Biol.** 3: 449-462.
- Wishka, D.G., D.R. Graber, L.A. Kopta, R.A. Olmsted, J.M. Friis, J.D. Hosley, W.J. Adams, E.P. Seest, T.M. Castle, L.A. Dolak, B.J. Keiser, Y. Yagi, A. Jeganathan, S.T. Schlachter, M.J. Murphy, G.J. Cleek, R.A. Nugent, S.M. Poppe, S.M. Swaney, F. Han, W. Watt, W.L. White, T. Poel, R.C. Thomas, R.L. Voorman, K.J. Stefanski, R.G. Stehle, W.G. Tarpley and J. Morris. 1998. (-)-6-Chloro-2-[(1-furo[2,3-*c*]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. **J. Med. Chem.** 41: 1357-1360.
- Zhou, Z., M. Madrid and J.D. Madura. 2002. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase. **PROTEINS: Structure, Function, and Genetics** 49: 529-542.
- Zhou, Z. and J.D. Madura. 2004. CoMFA: 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment. **J. Chem. Inf. Comput. Sci.** 44: 2167-2178.